MA34094B1 - Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2 - Google Patents

Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2

Info

Publication number
MA34094B1
MA34094B1 MA35260A MA35260A MA34094B1 MA 34094 B1 MA34094 B1 MA 34094B1 MA 35260 A MA35260 A MA 35260A MA 35260 A MA35260 A MA 35260A MA 34094 B1 MA34094 B1 MA 34094B1
Authority
MA
Morocco
Prior art keywords
prostaglandin
tetrahydro
receptor
modulators
heteroarylamino
Prior art date
Application number
MA35260A
Other languages
Arabic (ar)
English (en)
Inventor
Hamed Aissaoui
Heinz Fretz
Julien Hazemann
Sylvia Richard-Bildstein
Romain Siegrist
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MA34094B1 publication Critical patent/MA34094B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

La présente invention concerne des dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole représentés par la formule (i), dans laquelle r1, r2 et r3 sont tels que décrits dans la description, ainsi que leur utilisation comme modulateurs de récepteurs de prostaglandine, plus particulièrement comme modulateurs du récepteur de la prostaglandine d2, dans le traitement de diverses maladies et divers troubles à médiation par la prostaglandine. L'invention concerne également des compositions pharmaceutiques contenant ces composés et des procédés pour leur préparation.
MA35260A 2010-03-22 2011-03-21 Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2 MA34094B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2010051228 2010-03-22
PCT/IB2011/051165 WO2011117798A1 (fr) 2010-03-22 2011-03-21 Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2

Publications (1)

Publication Number Publication Date
MA34094B1 true MA34094B1 (fr) 2013-03-05

Family

ID=43929122

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35260A MA34094B1 (fr) 2010-03-22 2011-03-21 Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2

Country Status (28)

Country Link
US (1) US8697869B2 (fr)
EP (1) EP2558447B1 (fr)
JP (1) JP5291265B2 (fr)
KR (1) KR101444572B1 (fr)
CN (1) CN102791689B (fr)
AR (1) AR080703A1 (fr)
AU (1) AU2011231208B2 (fr)
BR (1) BR112012024114B1 (fr)
CA (1) CA2790139C (fr)
CL (1) CL2012002570A1 (fr)
CY (1) CY1115800T1 (fr)
DK (1) DK2558447T3 (fr)
ES (1) ES2524079T3 (fr)
HR (1) HRP20141208T1 (fr)
IL (1) IL221977A (fr)
MA (1) MA34094B1 (fr)
MX (1) MX2012010820A (fr)
MY (1) MY183111A (fr)
NZ (1) NZ603108A (fr)
PH (1) PH12012501863A1 (fr)
PL (1) PL2558447T3 (fr)
PT (1) PT2558447E (fr)
RU (1) RU2562255C2 (fr)
SG (1) SG183835A1 (fr)
SI (1) SI2558447T1 (fr)
TW (1) TWI562987B (fr)
WO (1) WO2011117798A1 (fr)
ZA (1) ZA201207894B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor
CN103450218B (zh) * 2012-05-29 2015-12-23 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的吲哚类三并环衍生物
ES2690782T3 (es) 2012-10-24 2018-11-22 Nyu Winthrop Hospital Biomarcador no invasivo para identificar sujetos en riesgo de parto prematuro
JP6479818B2 (ja) * 2013-05-10 2019-03-06 シーエヌアイシー ファンデーション セントロ ナショナル デ インベスティゲイショネス カーディオバスキュレアス カルロス ザ サード 骨髄増殖性新生物の治療に適した化合物
PE20161177A1 (es) * 2014-03-17 2016-11-18 Actelion Pharmaceuticals Ltd Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2
WO2015140701A1 (fr) 2014-03-18 2015-09-24 Actelion Pharmaceuticals Ltd Dérivés d'acide aza-indol-acétique et leur utilisation comme modulateurs des récepteurs de la prostaglandine d2
KR20180053345A (ko) * 2015-09-15 2018-05-21 이도르시아 파마슈티컬스 리미티드 결정질 형태
CA3075688A1 (fr) 2017-09-13 2019-03-21 Progenity, Inc. Biomarqueurs de pre-eclampsie ainsi que systemes et procedes associes
EP4070113A4 (fr) 2019-12-04 2023-12-20 Biora Therapeutics, Inc. Évaluation de la prééclampsie à l'aide de dosages du facteur de croissance placentaire libre et dissocié
CN113995758B (zh) * 2021-11-04 2023-06-02 中山大学 咔唑-嘧啶衍生物在制备治疗抗肿瘤药物中的应用
AU2024326262A1 (en) * 2023-08-13 2026-03-26 GATC Health Corp Compounds and methods for treating addiction

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808608A (en) 1986-01-23 1989-02-28 Merck & Co., Inc. Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
DE3631824A1 (de) 1986-02-21 1988-03-31 Bayer Ag Cycloalkano(1.2-b)indol-sulfonamide
ID23053A (id) * 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
ATE311200T1 (de) 2000-04-12 2005-12-15 Merck Frosst Canada Inc Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
US20010047027A1 (en) 2000-04-12 2001-11-29 Marc Labelle Prostaglandin D2 receptor antagonists
AU2002302248B2 (en) 2001-05-23 2008-03-06 Merck Frosst Canada Ltd. Dihydropyrrolo[1,2-A]indole and tetrahydropyrido[1,2-A]-indole derivatives as prostaglandin D2 receptor antagonists
WO2003051837A2 (fr) 2001-12-14 2003-06-26 Zentaris Gmbh Derives tetrahydrocarbazol servant de ligands de recepteurs couples aux proteines g (gpcr)
DE10164564B4 (de) * 2001-12-14 2007-05-16 Zentaris Gmbh Tetrahydrocarbazolderivate als Liganden für G-Protein gekoppelte Rezeptoren (GPCR)
AR038136A1 (es) 2002-01-24 2004-12-29 Merck Frosst Canada Inc Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003231509A1 (en) 2002-05-16 2003-12-02 Shionogi And Co., Ltd. Compound exhibiting pgd 2 receptor antagonism
WO2003097042A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Antagoniste de recepteur de pdg2
GB2388540A (en) 2002-05-17 2003-11-19 Bayer Ag New use of Ramatroban
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
WO2004039807A1 (fr) 2002-10-30 2004-05-13 Merck Frosst Canada & Co. Pyridopyrrolizine et derives de pyridoindolizine
JPWO2004078719A1 (ja) 2003-03-06 2006-06-08 小野薬品工業株式会社 インドール誘導体化合物およびその化合物を有効成分とする薬剤
US20070054951A1 (en) 2003-05-20 2007-03-08 Lianhai Li Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2004111047A2 (fr) 2003-06-12 2004-12-23 Merck Frosst Canada Ltd. Cycloalkanepyrrolopyridines utilisees comme antagonistes du recepteur dp
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
WO2005033099A2 (fr) 2003-10-03 2005-04-14 Glenmark Pharmaceuticals Ltd. Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant
US20070232681A1 (en) 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
WO2005040112A1 (fr) 2003-10-14 2005-05-06 Oxagen Limited Composes a activite antagoniste de pgd2
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB2407318A (en) 2003-10-23 2005-04-27 Oxagen Ltd Substituted Indol-3-yl acetic acid derivatives
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
US7019022B2 (en) * 2003-12-15 2006-03-28 Merck Frosst Canada & Co. Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
CN100584844C (zh) 2004-01-31 2010-01-27 艾克提麦斯医药品有限公司 咪唑[1,2-c]嘧啶基乙酸衍生物
US7714132B2 (en) 2004-03-11 2010-05-11 Actelion Pharmaceuticals, Ltd. Tetrahydropyridoindole derivatives
JP4861976B2 (ja) 2004-03-11 2012-01-25 アクテリオン ファーマシューティカルズ リミテッド インドール−１−イル酢酸誘導体
US20050234030A1 (en) 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
FR2869878B1 (fr) 2004-05-04 2006-08-04 Mecan Outil Sa Sa Procede et dispositif d'emballage d'objets allonges fragiles
GB0412914D0 (en) 2004-06-10 2004-07-14 Oxagen Ltd Compounds
MY144903A (en) 2004-06-17 2011-11-30 Novartis Ag Pyrrolopyridine derivatives and their use as crth2 antagonists
EP1814865A4 (fr) 2004-09-21 2009-09-02 Wyeth Corp Acides benzimidazole acetiques presentant un antagonisme du recepteur crth2 et utilisations associees
WO2006034419A2 (fr) 2004-09-21 2006-03-30 Athersys, Inc. Acides indole acetiques antagonistes du recepteur crth2 et ses utilisations
GB0427381D0 (en) 2004-12-14 2005-01-19 Novartis Ag Organic compounds
CA2594280C (fr) 2004-12-27 2013-04-23 Anja Fecher Derives de 2,3,4,9-tetrahydro-1h-carbazole utilises en tant qu'antagonistes des recepteurs de crth2
DOP2006000016A (es) 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422830A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
GB2422829A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
NZ560513A (en) 2005-02-25 2010-07-30 Ono Pharmaceutical Co Indole compound and use thereof
GB0504150D0 (en) 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
PL1891075T3 (pl) 2005-05-24 2011-12-30 Merck Serono Sa Spiropochodne tricykliczne jako modulatory CRTH2
GB0512944D0 (en) 2005-06-24 2005-08-03 Argenta Discovery Ltd Indolizine compounds
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
EP2397476A3 (fr) 2005-07-22 2011-12-28 Shionogi & Co., Ltd. Dérivé d'indole doté d'une activité antagoniste de récepteur PGD2
US7696222B2 (en) 2005-08-12 2010-04-13 Merck Frosst Canada Ltd Indole derivatives as CRTH2 receptor antagonists
US20070203209A1 (en) 2005-08-18 2007-08-30 Wilmin Bartolini Useful indole compounds
EP1932839A4 (fr) 2005-09-06 2014-09-10 Shionogi & Co Dérivé d acide indolécarboxylate ayant une activité à effet antagoniste du récepteur pgd2
GB0518783D0 (en) 2005-09-14 2005-10-26 Argenta Discovery Ltd Indolizine compounds
GB0521275D0 (en) 2005-10-19 2005-11-30 Argenta Discovery Ltd 3-Aminoindole compounds
GB0525143D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525141D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525144D0 (en) 2005-12-09 2006-01-18 Novartis Ag Organic compounds
GB0525337D0 (en) 2005-12-13 2006-01-18 Novartis Ag Organic compounds
GB0605743D0 (en) 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
GB0611695D0 (en) 2006-06-13 2006-07-26 Novartis Ag Organic compounds
CA2658496A1 (fr) 2006-07-22 2008-01-31 Oxagen Limited Derives d'acide acetique 2-(5-fluoro-2-methyl-3-{2-(phenylsulfonyl)benzyl et esters de ceux-ci ayant une activite antagoniste crth2
BRPI0714554A2 (pt) 2006-07-25 2013-05-07 Sanofi Aventis 2-fenil-indàis como antagonistas do receptor de prostaglandina d2
ATE530523T1 (de) * 2006-08-07 2011-11-15 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)- essigsäurederivate
AU2006352195A1 (en) 2006-12-21 2008-06-26 Argenta Discovery Limited CRTH2 antagonists
GB0625842D0 (en) 2006-12-22 2007-02-07 Argenta Discovery Ltd Indolizine derivatives
EP2136804A1 (fr) 2007-03-21 2009-12-30 Argenta Oral Therapeutics Limited Dérivés indolizine d'acide acétique utilisés comme antagonistes de crth2
GB0719485D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
GB0719521D0 (en) 2007-10-05 2007-11-14 Argenta Discovery Ltd Compounds
RU2451019C2 (ru) 2007-10-10 2012-05-20 КЕМИТЕК, ЭлЭлСи Гетероциклические соединения в качестве антагонистов crth2 рецептора
WO2009061676A2 (fr) 2007-11-06 2009-05-14 Amira Pharmaceuticals, Inc. Antagonistes de récepteurs pgd2
GB0722203D0 (en) 2007-11-13 2007-12-19 Oxagen Ltd Use of CRTH2 antagonist compounds
GB0722216D0 (en) 2007-11-13 2007-12-27 Oxagen Ltd Use of crth2 antagonist compounds
DK2229358T3 (da) 2007-12-14 2011-07-04 Pulmagen Therapeutics Asthma Ltd Indoler og deres terapeutiske anvendelse
CA2712017C (fr) 2008-01-18 2016-08-09 Oxagen Limited Composes presentant une activite antagoniste de crth2
WO2009090399A1 (fr) 2008-01-18 2009-07-23 Argenta Discovery Limited Indoles actifs sur le récepteur crth2
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
EP2265581A1 (fr) 2008-01-22 2010-12-29 Oxagen Limited Composés présentant une activité antagoniste du récepteur crth2
JP2011509991A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
JP2011088826A (ja) 2008-01-31 2011-05-06 Astellas Pharma Inc 芳香族カルボン酸化合物
US20110112134A1 (en) 2008-05-16 2011-05-12 Amira Pharmaceuticals, Inc. Tricyclic Antagonists of Prostaglandin D2 Receptors
WO2010008864A2 (fr) 2008-06-24 2010-01-21 Amira Pharmaceuticals, Inc. Antagonistes de cycloalcane[b]indole de récepteurs de prostaglandine d2
EP2307382B1 (fr) 2008-07-15 2011-12-21 F. Hoffmann-La Roche AG Acides aminotétrahydroindazoloacétiques
US8138208B2 (en) 2008-07-15 2012-03-20 Hoffmann-La Roche Inc. Aminotetrahydroindazoloacetic acids
CA2736571A1 (fr) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Derives d'azaindole comme antagonistes du recepteur crth2
US8637671B2 (en) 2008-09-22 2014-01-28 Merck Canada Inc. Indole derivatives as CRTH2 receptor antagonists
WO2010031182A1 (fr) 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Dérivés d'indole utilisables en tant qu'antagonistes du récepteur crth2
WO2010039982A1 (fr) 2008-10-01 2010-04-08 Ironwood Pharmaceuticals, Inc. Modulateurs de crth2
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
US20110311483A1 (en) 2010-03-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Crth2 modulators
DK2697223T3 (en) 2011-04-14 2016-09-05 Actelion Pharmaceuticals Ltd 7- (heteroaryl-amino) -6,7,8,9-tetrahydro-pyrido [1,2-a] indole-acetic acid derivatives and their use as prostaglandin D2 receptor

Also Published As

Publication number Publication date
JP2013522355A (ja) 2013-06-13
AU2011231208B2 (en) 2015-03-26
CY1115800T1 (el) 2017-01-25
MX2012010820A (es) 2012-10-10
PH12012501863A1 (en) 2021-06-23
WO2011117798A1 (fr) 2011-09-29
EP2558447A1 (fr) 2013-02-20
US8697869B2 (en) 2014-04-15
SG183835A1 (en) 2012-10-30
KR20130004922A (ko) 2013-01-14
US20130065902A1 (en) 2013-03-14
TWI562987B (en) 2016-12-21
EP2558447B1 (fr) 2014-09-17
KR101444572B1 (ko) 2014-09-24
CN102791689B (zh) 2014-10-29
BR112012024114B1 (pt) 2021-02-09
RU2012144543A (ru) 2014-04-27
AU2011231208A1 (en) 2012-11-08
AR080703A1 (es) 2012-05-02
ZA201207894B (en) 2014-03-26
CN102791689A (zh) 2012-11-21
CA2790139C (fr) 2018-03-13
CA2790139A1 (fr) 2011-09-29
IL221977A (en) 2014-09-30
BR112012024114A2 (pt) 2018-05-08
TW201139373A (en) 2011-11-16
SI2558447T1 (sl) 2015-01-30
JP5291265B2 (ja) 2013-09-18
NZ603108A (en) 2014-05-30
DK2558447T3 (da) 2014-11-10
HRP20141208T1 (hr) 2015-02-13
MY183111A (en) 2021-02-15
IL221977A0 (en) 2012-12-02
ES2524079T3 (es) 2014-12-04
PT2558447E (pt) 2014-11-25
PL2558447T3 (pl) 2015-03-31
CL2012002570A1 (es) 2012-12-21
HK1181048A1 (en) 2013-11-01
RU2562255C2 (ru) 2015-09-10

Similar Documents

Publication Publication Date Title
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
WO2008152099A3 (fr) Aryl/hétarylamides en tant que modulateurs du récepteur ep2
WO2012009009A3 (fr) Nouveaux dérivés de 2-amino-4-pyrazolyl-thiazole et leur utilisation en tant que modulateurs allostériques des récepteurs métabotropiques du glutamate
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
MX2010005861A (es) Agonistas novedosos de los receptores de glucocorticoides.
EA200970612A1 (ru) Производные индола в качестве агонистов рецептора s1p1
EA201190139A1 (ru) Производные тиенопиримидиндиона в качестве модуляторов trpa1
EA201390947A1 (ru) Соединения 2-амино-4-арилтиазола в качестве антагонистов trpa1
ATE469144T1 (de) Substituierte pyridonverbindungen und anwendungsverfahren
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
WO2011006935A3 (fr) Dérivés de tétrazole
WO2009025785A3 (fr) Ligands de récepteur cb2 pour le traitement de la douleur
EA201190004A1 (ru) Конденсированные имидазол карбоксамиды в качестве модуляторов trpv3
MA32943B1 (fr) Piperidine spiro pyrrolidione et piperidinone substituees, leur preparation et leur utilisation therapeutique
GEP20135806B (en) Lactams as beta secretase inhibitors
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
ATE430744T1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
MX2009010374A (es) Derivados de tetrahidro-naftalenamina sustituidos con heterociclilo, su preparacion y su uso como medicamentos.
EA200870606A1 (ru) Серосодержащие производные пиразола в качестве избирательных антагонистов рецептора каннабиноидов св
MA32945B1 (fr) Tétrahydropyrane spiro pyrrolidinone et pipéridinone substituées, leur préparation et leur utilisation thérapeutique
EA201001566A1 (ru) Новый класс спиропиперидинов для лечения нейродегенеративных заболеваний
MA32479B1 (fr) Compoés nouveaux actifs comme antagonistes des recepteurs muscariniques
EA200970849A1 (ru) Трициклические производные изохинолина для лечения ожирения